Home LiteratureArticle Details
PMID: 9228960 Published · ppublish English Comparative Study Journal Article Research Support, Non-U.S. Gov't

Radiation and genetic factors in the risk of second malignant neoplasms after a first cancer in childhood.

Lancet (London, England) ·Vol. 350 ·No. 9071 ·1997-07-12 ·Pages 91-5

Kony SJ, de Vathaire F, Chompret A, Shamsaldim A, Grimaud E, Raquin MA, Oberlin O, Brugières L, Feunteun J, Eschwège F, Chavaudra J, Lemerle J, Bonaïti-Pellié C

Abstract

Radiotherapy and chemotherapy are associated with an increased risk of second malignant neoplasm (SMN). An association between SMN and familial aggregation has also been shown. The aim of this study was to investigate the role of familial factors in the risk of SMN and their potential interaction with the effect of treatment. We devised a case-control study of 25 children with SMN (cases) and 96 children with no SMN after a cancer treatment (controls), taken from a cohort of 649 children treated at our institution between 1953 and 1985. A complete family history was obtained for patients and controls and a familial index defined to evaluate the degree of familial aggregation. The radiation dose given at 151 sites in the body was estimated for each radiotherapy course for each child. Among family members of the 25 SMN cases, there were ten with early-onset (< or = 45 years) cancer, compared with eight among relatives of the 96 controls. Compared with patients who had no family history of early-onset cancer, those with one or more affected family members had an odds ratio for SMN of 4.7 (95% CI 1.3-17.1; p = 0.02). Adjustment for local radiation dose and exclusion of patients known to be predisposed to SMN (carriers of p53 mutation and those with Recklinghausen's disease) did not affect this risk substantially. Both genetic factors and exposure to ionising radiation have independent effects on the risk of SMN. Follow-up of children treated for cancer should be especially vigilant when there is a family history of early-onset cancer.

MeSH Terms
Adolescent Age of Onset Antineoplastic Combined Chemotherapy Protocols/classification,therapeutic use Case-Control Studies Child Child, Preschool Cohort Studies Female Follow-Up Studies Genes, p53/genetics Heterozygote Humans Incidence Lymphoma/radiotherapy Male Middle Aged Mutation/genetics Neoplasms/genetics Neoplasms, Second Primary/etiology Neurofibromatosis 1/genetics Odds Ratio Radiotherapy/adverse effects Radiotherapy Dosage Risk Factors Sarcoma/radiotherapy Wilms Tumor/radiotherapy
Authors & Affiliations
13 authors, click to expand affiliations / ORCID
Kony S J
Research Unit of Cancer Epidemiology (U351 INSERM), Villejuif, France.
de Vathaire F
Chompret A
Shamsaldim A
Grimaud E
Raquin M A
Oberlin O
Brugières L
Feunteun J
Eschwège F
Chavaudra J
Lemerle J
Bonaïti-Pellié C
Article Info
Journal
Lancet (London, England)
Abbr.
Lancet
ISSN
0140-6736
Published
1997-07-12
Pages
91-5
Language
English
Region
England
NLM ID
2985213R
Subset
IM
Corrections
CommentIn
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]